PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
- Conditions
- Invasive AspergillosisMucormycosis
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT04550936
- Locations
- 🇫🇷
Hôpital Huriez CHU de Lille, Lille, France
🇫🇷Institut de Cancérologie, Strasbourg, France
🇫🇷CHU de Limoges, Limoges, France
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20-valent pneumococcal conjugate vaccineBiological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1258
- Registration Number
- NCT04546425
- Locations
- 🇦🇺
Perth Children's Hospital, Nedlands, Western Australia, Australia
🇦🇺Telethon Kids Institute, Vaccine Trials Group, Perth Children's Hospital, Nedlands, Western Australia, Australia
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
- Conditions
- Brain Neoplasms, PrimaryMalignant NeoplasmsMalignant MelanomaBrain NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT04543188
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
- Conditions
- Household Contacts
- Interventions
- Other: Blood Draw
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04543357
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
Study To Evaluate The Pharmacokinetic, Safety And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT04543344
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT04541706
- Locations
- 🇮🇳
Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India
🇮🇳The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India
🇮🇳Apex Wellness Hospital, Nashik, Maharashtra, India
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26
- Registration Number
- NCT04535167
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸Massachusetts General Hospital Translational and Clinical Research Center, Boston, Massachusetts, United States
🇧🇪University Hospital Brugmann, Brussels, Belgium
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 20-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 668
- Registration Number
- NCT04530838
- Locations
- 🇯🇵
Inami Pediatrics, Setagaya-ku, Tokyo, Japan
🇯🇵Saitoh-Clinic, Nishitokyo-shi, Tokyo, Japan
🇯🇵Futaba Clinic, Shinjuku-ku, Tokyo, Japan
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)Other: SalineBiological: Influenza vaccine
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1796
- Registration Number
- NCT04526574
- Locations
- 🇺🇸
Indago Research and Health Center, Inc., Hialeah, Florida, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸East Valley Gastroenterology and Hepatology Associates, Chandler, Arizona, United States
Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
- Conditions
- Psoriatic Arthritis
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 116
- Registration Number
- NCT04517669
- Locations
- 🇮🇱
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel
🇮🇱Hadassah Hebrew University Medical Center - Ein Kerem, Jerusalem, Israel
🇮🇱Meir Medical Center, Kfar- Sava, Israel